Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Defends King Deal, Cites “Growing Appreciation” Among Investors

This article was originally published in The Pink Sheet Daily

Executive Summary

Investor feedback on merger is “positive,” Mylan says in response to attempt by investor Carl Icahn to block proposed deal. Mylan dismisses Icahn’s opposition as opportunistic.

You may also be interested in...



Icahn's $5.4 Bil. Bid For Mylan Leaves Door Open To A "White Knight" Suitor

Investor offers $20 per share, a 17% premium over Mylan's closing price a day earlier. Icahn suggests other pharma companies are potentially interested in buying the generic drug maker and is proposing an acquisition contract with no break-up fee so that Mylan could pursue other offers.

Icahn's $5.4 Bil. Bid For Mylan Leaves Door Open To A "White Knight" Suitor

Investor offers $20 per share, a 17% premium over Mylan's closing price a day earlier. Icahn suggests other pharma companies are potentially interested in buying the generic drug maker and is proposing an acquisition contract with no break-up fee so that Mylan could pursue other offers.

Altace Patent Suit Cited By Icahn In Latest Missive Against Mylan/King Merger

Investor maintains that Cobalt Pharmaceuticals' patent challenge could mean a generic version of the ACE inhibitor will be launched in mid-2005. Mylan suggests that Icahn's opposition is motivated in part by desire to cash-in on short position in King.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel